I agree that this site is using cookies. You can find further informations here.
X
Szarek, Michael
223  results:
Search for persons X
?
1

Time to clinical benefit with sotagliflozin in patients wit..:

Aggarwal, Rahul ; Bhatt, Deepak L. ; Szarek, Michael...
European Journal of Heart Failure.  26 (2024)  4 - p. 1093-1095 , 2024
Link: https://doi.org/10.1002/..
 
?
2

Safety of the PCSK9 inhibitor alirocumab: insights from 47 ..:

Goodman, Shaun G ; Steg, Philippe Gabriel ; Szarek, Michael...
European Heart Journal - Cardiovascular Pharmacotherapy.  , 2024
Link: https://doi.org/10.1093/..
 
?
3

Relating Lipoprotein(a) Concentrations to Cardiovascular Ev..:

Szarek, Michael ; Reijnders, Esther ; Jukema, J. Wouter...
Circulation.  149 (2024)  3 - p. 192-203 , 2024
Link: https://doi.org/10.1161/..
 
?
4

Alirocumab and cardiovascular outcomes according to sex and..:

Bittner, Vera A. ; Schwartz, Gregory G. ; Bhatt, Deepak L....
Journal of Clinical Lipidology.  , 2024
Link: https://doi.org/10.1016/..
 
?
5

Comparison of change in lipoprotein(a) mass and molar conce..:

Szarek, Michael ; Reijnders, Esther ; Steg, Ph Gabriel...
European Journal of Preventive Cardiology.  , 2024
Link: https://doi.org/10.1093/..
 
?
6

How Generalizable Is The Soloist-whf Trial In 'Real World' ..:

Canonico, Mario Enrico ; Hsia, Judith ; Szarek, Michael..
Journal of Cardiac Failure.  30 (2024)  1 - p. 228 , 2024
Link: https://doi.org/10.1016/..
 
?
7

Quantitative Benefit–Risk Evaluation of Rivaroxaban in Pati..:

Yuan, Zhong ; Levitan, Bennett ; Deng, Hsiaowei...
Journal of the American Heart Association.  13 (2024)  8 - p. , 2024
Link: https://doi.org/10.1161/..
 
?
8

Lipoprotein(a) Blood Levels and Cardiovascular Risk Reducti..:

Szarek, Michael ; Bhatt, Deepak L. ; Miller, Michael...
Journal of the American College of Cardiology.  83 (2024)  16 - p. 1529-1539 , 2024
Link: https://doi.org/10.1016/..
 
?
9

Sotagliflozin and Kidney Outcomes, Kidney Function, and Alb..:

Sridhar, Vikas S. ; Bhatt, Deepak L. ; Odutayo, Ayodele...
Clinical Journal of the American Society of Nephrology.  19 (2024)  5 - p. 557-564 , 2024
Link: https://doi.org/10.2215/..
 
?
10

Lipoprotein(a) and the Effect of Alirocumab on Revasculariz..:

Steg, P. Gabriel ; Szarek, Michael ; Valgimigli, Marco...
Canadian Journal of Cardiology.  39 (2023)  10 - p. 1315-1324 , 2023
Link: https://doi.org/10.1016/..
 
?
11

Novel Tissue Factor Inhibition for Thromboprophylaxis in CO..:

Hess, Connie N. ; Hsia, Judith ; Carroll, Ian A....
Arteriosclerosis, Thrombosis, and Vascular Biology.  43 (2023)  8 - p. 1572-1582 , 2023
Link: https://doi.org/10.1161/..
 
?
12

Transiently achieved very low LDL-cholesterol levels by sta..:

Schwartz, Gregory G ; Szarek, Michael ; Bhatt, Deepak L...
European Heart Journal.  , 2023
Link: https://doi.org/10.1093/..
 
?
13

Efficacy of Sotagliflozin in Adults With Type 2 Diabetes in..:

Aggarwal, Rahul ; Bhatt, Deepak L. ; Szarek, Michael...
Journal of the American College of Cardiology.  82 (2023)  19 - p. 1842-1851 , 2023
Link: https://doi.org/10.1016/..
 
?
14

Rivaroxaban in patients with symptomatic peripheral artery ..:

Govsyeyev, Nicholas ; Nehler, Mark ; Conte, Michael S....
European Journal of Vascular and Endovascular Surgery.  65 (2023)  4 - p. e45-e46 , 2023
Link: https://doi.org/10.1016/..
 
?
15

Long‐Term Efficacy, Safety, and Tolerability of Alirocumab ..:

Goodman, Shaun G. ; Steg, Philippe Gabriel ; Poulouin, Yann...
Journal of the American Heart Association.  12 (2023)  18 - p. , 2023
Link: https://doi.org/10.1161/..
 
1-15